One of the D.C. region’s largest biotechs is working to be among the first publicly traded companies in its industry to convert to a public benefit corporation — an entity that must answer to both shareholders and society at large.
United Therapeutics Corp. (NASDAQ: UTHR) will seek approval from those shareholders at a Sept. 30 meeting to make the change in its certificate of incorporation, after which it would not only report financial results but also its effect on environmental, social and governance priorities on a regular basis. Company officials say the legal change will not alter its business or leadership strategy.
Read the full story in the Washington Business Journal.

留言